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Background and aim: Minimal hepatic encephalopathy (MHE)
is the earliest form of hepatic encephalopathy (HE) and can affect
up to 80% of patients with liver cirrhosis. It is characterized by
impaired cognitive function; mainly in the domains of attention,
memory, speed of response, surveillance and integrative function.
Patients with MHE show reduced performance in selective and
which has a negative impact on the patients’ health-related quality
of life. Currently, there is no gold standard for diagnosis of EHM.
Reports Montoluiu et al. evaluated the serum levels of different
nitro-oxidative stress metabolites, cyclic guanosine monophos-
phate (cGMP), nitrites + nitrates and 3-nitrotyrosine (3-NO-Tyr);
For each metabolite, its diagnostic precision was evaluated as an
indicator of MHE, correlating it with the level of performance in
psychometric tests for the diagnosis of HE as a comparison, find-
ing high sensitivity and specificity for 3-nitrotyrosine. Despite the
fact that 3-NO-Tyr has been evaluated in EHM, there is a wide vari-
ation of results that support its clinical utility, mainly due to the
quantification methods used. AIM. To develop an analytical method
to quantify the products of nitro-oxidative stress 3-NO-Tyr and
3-chloro-Tyrosine (3-Cl-Tyr) of high sensitivity and specificity to
quantify the levels of these metabolites in samples from partici-
pating subjects with liver damage and MHE and comparing against
the levels of subjects with liver damage without MHE, as well as
the baseline level in healthy control subjects.
Material and methods: This study was approved by the Insti-
tute’s Ethics and Research Committee. An analytical method was
developed for the quantification of 3-NO-Tyr as 3-Cl-Tyr by means
of triple quadrupole mass spectrometry coupled to an ultra high
efficiency liquid chromatography system (UPLC-MS / MS XEVO TqD
Waters). The spectrometer was programmed using the molecu-
lar transitions of NO-Tyr (227.2> 181.1), Cl-Tyr (216.2> 170.1) and
the internal standard (EI) (132.2 > 86.2) for the internal standard
respectively. The samples were hydrolyzed prior to processing and
analysis to quantify free and protein-derived metabolites.
Results: The method was linear in the range of 0.5 - 2500 nM
for both metabolites, it met the validation tests of the analytical
methods. The results show that, by means of the developed method,
it is possible to perform the simultaneous quantification of free
3-NO-Tyr and Cl-Tyr and protein derivatives, so it can be used to
quantify them in samples of MHE, non-MHE and control subjects.
Conclusions: With the developed method, it is possible to
accurately and precisely quantify the concentrations of both
metabolites in the proposed biological matrix, so if they show dif-
ferences between study groups, they could be used to determine
them in the early diagnosis of MHE.
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Background and aim: Nowadays there are several treatments
for hepatocellular carcinoma BCLC B, among them is radioem-
bolization with Itrio-90 (RE-Y90) which is a form of locoregional
intra-arterial brachytherapy towards HCC, among its advantages is
prolonging the HCC progression time and improve the quality of life
of patients. Adverse effects could be extrahepatic (radiation pneu-
monitis) and intrahepatic (radiation-induced liver disease), among
others. Objective of our work is to assess the time free of progres-
sion, response to treatment and adverse effects that occur with the
administration of RE-Y90.
Material and methods: All HCC BCLC B patients who were can-
didates for RE-Y90 were analyzed.
Inclusion criteria: cirrhotic patients of any etiology, with a
diagnosis of HCC stage B, Child Pugh A and B with 7 points, who
had previously undergone a morphological study (CT / MRI) and
arteriography to characterize the lesion, to know the irrigation of
the tumor and rule out extrahepatic shunts that contraindicate
the application of RE-Y90. Subsequently, the procedure was simu-
lated with MAA-Tc99m in order to record its distribution, perform
dosimetry, and on the day of RE-Y90, an image study was performed
with PET / CT in order to verify the distribution. Exclusion criteria.
Patients with liver cirrhosis of any etiology with BCLC Stage B of
the Child Pugh B plus 7 points or those with Child Pugh A or B 7
points with extrahepatic shunts. Do not accept this type of therapy.
Patients who were not candidates for this therapy were sessioned
at the Gastrointestinal and Liver Tumor Meeting to decide their
treatment. Response to treatment at 3 and 6 months was analyzed
using the mRECIST criteria, progression-free time at 6 months, and
adverse effects were recorded.
Results: Two patients with HCC BCLC B, a 70-year-old woman
with HCC from AIH and a 67-year-old man with HCC of alcohol
etiology, both Child Pugh at 6 points, with no data on arterial throm-
bosis, were performed.
